Last reviewed · How we verify
A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 60 |
| Start date | 2004-05 |
| Completion | 2007-10 |
Conditions
- Breast Cancer
Interventions
- gefitinib and fulvestrant
Primary outcomes
- To evaluate the progression-free survival (PFS) of the combination of 250 mg ZD1839 and fulvestrant in patients with advanced or metastatic breast cancer
Countries
Spain